Breakthrough in treatment of blood cancer patientsDaily EchoThe trial, of which part was carried out at the University of Southampton, revealed that the injection of the drug, rituximab, worked just as effectively as the tradition treatment. Dr Andrew …
|
CTI announces preclinical study of Pixuvri, provides mechanism for lower …
pharmabiz.com The EMA Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who have relapsed after one to three prior … |
|
Preclinical Study Provides Potential Mechanisms for Lower Cardiotoxicity in …
PharmaLive (press release) (subscription) The European Medicines Agency’s (the “EMA”) Committee for Medicinal Products for Human Use has accepted PIX306, CTI’s ongoing randomized controlled phase III clinical trial, which compares Pixuvri-rituximab to gemcitabine-rituximab in patients who … |
Norwegian Newspaper, News Site, Feature ME/CFS Patient Improved by …ProHealthOn Dec 13, the Norwegian newspaper Aftenposten posted a video on its site featuring an interview (in Norwegian) with Maria Gjerpe, one of the ME/CFS patients who improved si…
 MedPage Today |
HBV Screening Hit or Miss in Rituximab Users
MedPage Today ATLANTA — At least in one academic medical center, half of cancer patients on rituximab (Rituxan) were not screened for hepatitis B virus (HBV) infection as recommended, a researcher said here. A review of patients’ charts at UMass Memorial Health … |
|
Rituximab and 131iodine-tositumomab produce similar survival for follicular …
Curetoday.com (press release) NEW YORK (Reuters Health) – Added to standard CHOP chemotherapy, both rituximab and radioimmunotherapy (RIT) produce excellent results in patients presenting with advanced follicular lymphoma, a Southwest Oncology Group study shows. “My view of … |
|
Rituximab and 131iodine-tositumomab produce similar survival for follicular …
ModernMedicine NEW YORK (Reuters Health) – Added to standard CHOP chemotherapy, both rituximab and radioimmunotherapy (RIT) produce excellent results in patients presenting with advanced follicular lymphoma, a Southwest Oncology Group study shows. “My view of … |
|
Older and younger chronic leukemia patients may need different therapy
Science Codex “The study suggests that chlorambucil is superior to fludarabine in older patients, and that CD20 antibody therapies such as rituximab are beneficial as front-line therapy for all CLL patients, regardless of age,” says Byrd, who is the D. Warren Brown … |
|
New Combo Replaces CHOP for Lymphoma
MedPage Today ATLANTA – Once the most common treatment for indolent non-Hodgkin’s Lymphoma, the combination chemotherapy known as CHOP is rapidly falling to the wayside in Germany – replaced by bendamustine (Treanda), frequently combined with rituximab … |
|
Anti–PD-1 Immunotherapy Shows Activity in Relapsed Lymphoma Patients
Cancer Network The combination of rituximab (Rituxan) and the novel immunotherapy pidilizumab (CT-011) is both active and well tolerated in follicular lymphoma patients, according to results of a phase II trial presented by Jason R. Westin, MD, of the MD Anderson … |